VRTX · News · 20260822N

Guidance / Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-08-22 · Importance 75 · Surprise 60

Vertex raised its full-year 2026 revenue guidance to US$13.1 billion–US$13.2 billion. The increase reflects continued cystic-fibrosis treatment demand and growing contributions from CASGEVY and JOURNAVX in sickle-cell disease, beta thalassemia, and acute pain. The updated outlook supports management’s diversification strategy beyond the cystic-fibrosis franchise, although reporting continues to flag concentration risk.

Key facts

• Vertex's raised 2026 revenue guidance was attributed to strong demand for cystic fibrosis treatments and expanding use of its sickle cell disease, beta thalassemia, and acute pain therapies. source